Intraperitoneal chemotherapy in ovarian cancer

Cancer Treatment Reviews

Volumn 26, Issue 2, 2000, Pages 133-143

  Hofstra, L S ^a   De Vries, E G E ^a   Mulder, N H ^a   Willemse, P H B ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chemotherapy; Intraperitoneal; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; INTERFERON; MELPHALAN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PARACETAMOL; THIOTEPA; TOPOTECAN;

ABDOMINAL PAIN; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG USE; FEMALE; FEVER; HUMAN; HYPOTENSION; INTRAPERICARDIAL DRUG ADMINISTRATION; META ANALYSIS; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERITONEAL CAVITY; RASH; REVIEW; VOMITING;

EID: 0034035606     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0152     Document Type: Review

References (97)

1. Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 71:1993;517-523.
2. Cannistra S. A. Cancer of the ovary. N Engl J Med. 329:1993;1550-1559.
3. McGuire W. P., Hoskins W. J., Brady M. F. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med. 335:1996;1950-1955.
4. McGuire W. P., Ozols R. F. Chemotherapy of advanced ovarian cancer. Sem Oncol. 25:1998;340-348.
5. Bergman F. Carcinoma of the ovary. A clinopathological study of 86 autopsied cases with special reference to the mode of spread. Acta Obstet Gynecol Scand. 45:1966;211-231.
6. Dedrick R., Myers C., Bungay P. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 62:1978;1-11.
7. Babb A. L., Johasen P. J., Strand M. J. Biderectional permeability of the human - peritoneum to middle molecules. Proc Eur Dial Transplant Assoc. 10:1993;247-261.
8. Maher J. F. Peritoneal transport rates: Mechanisms, limitations and methods for augmentation. Kidney Int. 18:1980;117-120.
9. Litterst C. I., Torres I. J., Sikic B. I. Absorption of antineoplastic drugs following large volume IP administration to rats. Cancer Treat Rep. 66:1980;147-155.
10. Ozols R. F., Locker G. Y., Doroshow J. H. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian carcinoma. Cancer Res. 39:1979;3209-3214.
11. Los G., Verdegaal E., Mutsaers P. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 28:1991;159-165.
12. Markman M., Reichman B., Hakes T. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol Oncol. 50:1993;100-104.
13. Barakat R., Fennelly D., Pizutto F. Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: Impact of retroperitoneal nodal disease. Eur J Gynaecol Oncol. 18:1997;161-163.
14. Rosenhein N., Blake D., McIntyre P. The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol Oncol. 6:1978;106-110.
15. Levenback C., Curtin J., Johnston D. Image analysis of the distribution of intraperitoneally administered fluids in patients with ovarian cancer. Eur J Gynaecol Oncol. 15:1994;345-351.
16. Myers C. The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Semin Oncol. 11:1984;274-284.
17. Myers C. The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Semin Oncol. 11:1984;274-284.
18. Jenkins J., Sugarbaker P. H., Gianola F. J. Technical considerations in the use of of intraperitoneal chemotherapy administered by Tenckhoff catheter. Surg Gynecol Obstet. 154:1982;858-864.
19. Kaplan, Markman M., Lucas W. E. Infectious peritonitis in patients receiving intraperitoneal chemotherapy. Am J Med. 78:1985;49-53.
20. Almadrones L., Yerys C. Problems associated with the administration of intraperitoneal therapy using the Port-A-Cath system. Oncol Nurs Forum. 17:1990;75-80.
21. Malmstrom H., Carstensen J., Simonsen E. Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer patients. Gynecol Oncol. 54:1994;27-34.
22. Naumann R. W., Alvarez R. D., Partridge E. E. The Groshong catheter as an intraperitoneal access device in the treatment of ovarian cancer patients. Gynecol Oncol. 50:1993;291-293.
23. Howell S., Pfeifle C., Wung W. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 97:1982;845-851.
24. Pretorius R. G., Hacker N. F., Berek J. S. Pharmacokinetics of IP cisplatin in refractory ovarian carcinoma. Cancer Treat Rep. 67:1983;1085-1092.
25. Casper E. S., Kelsen D. P., Alcock N. W. IP cisplatin in patients with malignant ascites. Pharmacokinetic evaluation and comparison with the IV route. Cancer Treat Rep. 67:1983;235-238.
26. Malmstrom H., Larsson D., Simonsen E. Phase I study of intraperitoneal carboplatin as adjuvant therapy in early ovarian cancer. Gynecol Oncol. 39:1990;289-294.
27. Elferink F., Van der Vijgh W. J., Klein I. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol. 21:1988;57-60.
28. Guastella J. P., Lhomme C., Kerbrat P. Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. A multicentre study of the French federation Nationale des Centre de Lutte Contre le Cancer. Ann Oncol. 5:1994;127-132.
29. Speyer J. L., Sorich J. Intraperitoneal carboplatin: rationale and experience. Semin Oncol. 19:1992;107-113.
30. Markman M., Rowinsky E., Hakes T. Phase I trial of intraperitoneal Taxol: A Gynecologic Oncology Group Study. J Clin Oncol. 9:1992;1485-1491.
31. Francis P., Rowinsky E., Schneider J. Phase I feasibility and pharmacological study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group Pilot Study. J Clin Oncol. 13:1995;2961-2967.
32. Willemse P. H. B., Hofstra L. S., Beijnen J. H. Primary intraperitoneal paclitaxel combined with CBDCA/Cytoxan (CC) in advanced ovarian cancer: a phase II study. Proc Am Soc Clin Oncol. 16:1997;#1360.
33. Ten Bokkel Huinink W., Gore M., Carmichael J. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 15:1997;2183-2193.
34. Bookman M. A., Malmstrom H., Bolis G. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 16:1998;3345-3352.
35. Plaxe S. C., Christen R. D., O'Quigley J. Phase I and pharmacokinetic study of intraperitoneal topotecan. Invest New Drugs. 16:1998;147-153.
36. Hofstra L. S., De Vries E. G. E., Van der Zee A. G. J. Phase I/II and pharmacokinetic study of intraperitoneal topotecan. Proc Am Soc Clin Oncol. 17:1998;#935.
37. O'Dwyer P. J., LaCreta F. P., Daugherty J. P. Phase I pharmacokinetic study of intraperitoneal etoposide. Cancer Res. 51:1991;2041-2046.
38. Zimm S., Cleary S. M., Lucas W. E. Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res. 15:1987;1712-1716.
39. McClay Ef, Goel R., Andrews P. A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide. Br J Cancer. 68:1993;783-788.
40. Howell S. B., Pfeifle C. E., Olshen R. A. Intraperitoneal chemotherapy with melphalan. Ann Intern Med. 101:1984;14-18.
41. Piccart M. J., Abrams J., Dodion P. F. Intraperitoneal chemotherapy with cisplatin and melphalan. J Natl Cancer Inst. 80:1988;1118-1124.
42. Oza A. M., Ten Bokkel Huinink W., Dubbelman R. Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. Ann Oncol. 5:1994;343-347.
43. Alberts D. S., Surwit E. A., Peng Y. M. Phase I clinical and pharmacological study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res. 15:1988;5874-5877.
44. Nicoletto M. O., Padrini R., Ferrazzi E. Phase I-II intraperitoneal mitoxantrone in advanced pretreated patients. Eur J Cancer. 29:1993;1242-1248.
45. Blochl-Daum B., Eichler H. G., Rainer H. Escalating dose regimen of intra peritoneal mitoxantrone: phase I study-clinical and pharmacokinetic evaluation. Eur J Cancer Clin Oncol. 24:1988;1133-1138.
46. Husain A., Sabbatini P., Spriggs D. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer. Gynecol Oncol. 73:1999;96-101.
47. Kirmani S., McVey L., Loo D. A phase I clinical trial of intraperitoneal thiotepa for refractory ovarian cancer. Gynecol Oncol. 36:1990;331-334.
48. Wadler S., Egorin M. J., Zuhowski E. G. Phase I pharmacokinetic study of hiotepa administered intraperitoneally in patients with advanced malignancies. J Clin Oncol. 7:1989;132-139.
49. Sugarbaker P. H., Gianola F. J., Speyer J. C. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. 98:1985;412-422.
50. Kuzuya T., Yamauchi M., Ito A. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin-C in intraperitoneal chemotherapy. J Pharm Pharmacol. 46:1994;685-689.
51. Speyer J. L., Collins J. M., Dedrick R. L. Phase I and pharmacologic studies of 5-FU administered intraperitoneally. Cancer Res. 40:1980;567-572.
52. Howell S. B., Chu B. B., Wung H. E. Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest. 67:1981;1161-1170.
53. Jones R. B., Collins J. M., Myers C. E. High volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res. 41:1981;55-59.
54. Ozols R., Young R., Speyer J. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 42:1982;4265-4269.
55. Markman M., Howell S. B., Lucas W. E. Combination intraperitoneal chemotherapy with cisplatin, cytarabine and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol. 2:1984;1321-1326.
56. King M., Pfeifle C., Howell S. Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma. J Clin Oncol. 2:1984;662-669.
57. Piver S., Shasikant B., Marchetti D. Surgically documented response to intraperitoneal cisplatin, cytarabine and bleomycin after intravenous cisplatin based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol. 11:1988;1679-1684.
58. Markman M., Cleary S., Lucas W. E. Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. J Clin Oncol. 3:1985;925-931.
59. Bitran J. Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial. Cancer. 56:1985;2420-2423.
60. Howell S. B., Schieffer M., Andrews P. A. The pharmacology of intraperitoneally administered bleomycin. J Clin Oncol. 5:1987;2009-2016.
61. Markman M., Cleary S., Lucas W. IP chemotherapy employing a regimen of cisplatin, cytarabine and bleomycin. Cancer Treat Rep. 70:1986;755-760.
62. Alberts D. S., Liu P. Y., Hannigan E. V. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 335:1996;1950-1955.
63. Kirmani S., Braly P. S., McClay E. F. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol. 54:1994;338-344.
64. Markman M., Bundy B., Benda J. Randomized phase III study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatinum followed by IV PAC and intraperitoneal (IP) CIS in optimal residual ovarian cancer. Proc Am Soc Clin Oncol. 17:1998;#300.
65. Polyzos A., Tsavaris N., Kosmas C. A comparitive study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology. 56:1999;291-296.
66. Beller U., Speyer J., Colombo N. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer. J Clin Oncol. 9:1991;809-817.
67. Tarraza H., Boyce C., Smith W. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy. Gynecol Oncol. 50:1993;287-290.
68. Menczer J., Ben Baruch G., Rizel S. Intraperitoneal cisplatin in patients with ovarian carcinoma who are in clinically complete remission. Gynecol Oncol. 46:1992;222-225.
69. Barakat R., Almadrones L., Venkatraman E. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol. 69:1998;17-22.
70. Bruzzone M., Rubagotti A., Gadducci A. Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look laparotomy: a prospective randomized trial of 111 patients. Gynecol Oncol. 65:1997;499-505.
71. Pujade-Lauraine E., Guastalla J. P., Colombo N. Intraperitoneal interferon gamma in ovarian cancer patients with residual disease at second look. J Clin Oncol. 14:1996;343-350.
72. Dufour P., Bergerat J. P., Barats J. C. Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer. 73:1994;1865-1869.
73. Howell S., Zimm S., Markman. Long-term survival of advanced refractory ovarian carcinoma patients treated with small volume disease treated with intra-peritoneal chemotherapy. J Clin Oncol. 5:1987;1607-1612.
74. Markman M., Reichman B., Hakes T. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small volume residual ovarian cancer. J Clin Oncol. 10:1992;1479-1484.
75. De Jong R. S., Willemse P. H. B., Boonstra H. Phase II study of intraperitoneal cisplatin plus systemic etoposide as second line treatment in patients with small volume residual disease. Eur J Cancer. 31:1995;709-713.
76. Reichman B., Markman M., Hakes T. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J Clin Oncol. 7:1989;1327-1332.
77. Braly S. A phase II Gynecologic Oncology Group trial. Gynecol Oncol. 56:1995;164-168.
78. Piver S., Recio F., Baker T. Evaluation of survival after second-line intraperitoneal Cisplatin-based chemotherapy for advanced ovarian cancer. Cancer. 73:1994;1693-1698.
79. Markman M., Reichman B., Hakes T. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small volume residual ovarian cancer. J Clin Oncol. 10:1992;1479-1484.
80. Markman M., Reichman B., Hakes T. Responses to second line cisplatin based intraperitoneal chemotherapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol. 9:1991;1801-1805.
81. Recio F., Piver M., Hempling R. Five year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer. Gynecol Oncol. 68:1998;267-273.
82. Markman M., Brady M., Spirtos N. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube and peritoneum: A Gynecologic Oncology Group Study. J Clin Oncol. 16:1998;2620-2624.
83. Markman M. Intraperitoneal therapy of ovarian cancer. Sem Oncol. 25:1998;356-360.
84. Orlando M., Huertas E., Salum G. Intraperitoneal hyperthermic chemotherapy as consolidation treatment for ovarian cancer in pathological complete remission. Proc Am Soc Clin Oncol. 17:1998;#1432.
85. Alvarez R., Partridge E., Khazaeli M. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol. 65:1997;94-101.
86. Freedman R. S., Lenzi R., Kudelka A. P. Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines Cell Mol Ther. 4:1998;121-140.
87. Steller M. A., Egorin M. J., Trimble E. L. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high dose carboplatin as primary treatment of patients with small volume residual ovarian cancer. Cancer Chemother Pharmacol. 43:1999;106-114.
88. Berek J. S., Hacker N. F., Lichtenstein A. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarina cancer: a Gynecologic Oncology Group Study. Cancer Res. 45:1985;4447-4453.
89. Willemse P. H. B., De Vries E. G. E., Mulder N. H. Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer. Eur J Cancer. 26:1990;353-358.
90. Friedlander M., Millward M. J., Bell D. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol. 9:1998;1343-1345.
91. Pestieau S. R., Stuart O. A., Chang D. Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori. 84:1998;706-711.
92. Arts H. J., Willemse P. H. B., Tinga D. J. Laparoscopic placement of PAP catheters for intraperitoneal chemotherapy in ovarian carcinoma. Gynecol Oncol. 69:1998;32-35.
93. Nanninga A. G., Willemse P. H. B., Boonstra H. Low complication rate during intraperitoneal therapy through a totally implanted peritoneal access port in patients with ovarian cancer. Int J Gynecol Oncol. 2:1992;107-110.
94. Von Grueningen V. E., Santoso J. T., Coleman R. L. In vivo studies of adenovirus-based gene therapy for ovarian cancer. Gynecol Oncol. 69:1998;197-204.
95. Kim J., Hwang E. S., Kim J. S. Intraperitoneal gene therapy with adenoviral mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse. Cancer Gene Ther. 6:1999;172-178.
96. Heise C., Sampson J. A., Williams A. ONYX-015, an E1B gene attenuated adenovirus, causes tumor-specific cytolysis and antitumoral effects that can be augmented by standard chemotherapeutic agents. Nature Med. 3:1997;639-645.
97. Van der Zee A. G. J., Hollema H., Suurmeijer A. J. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol. 13:1995;70-78.